Intravenous diazepam application in a departmental convulsive status epilepticus protocol with CYP2C19 polymorphisms: a pediatric prospective cohort study Authors: Muazzez Seker Gezici, Caner Turan, Durdugul Ayyildiz Emecen, Seda Kanmaz, Esra Isik, Ali Yurtseven, Tahir Atik, Sanem Keskin Yilmaz, Hasan Tekgul, Eylem Ulas Saz Published: 2026 ABSTRACT AbstractBackgroundIndividual variability of therapeutic response and adverse effects of diazepam is frequently observed in pediatric cohorts. It might be related to the genetic polymorphisms in cytochrome P450 2C19 (CYP2C19), a principal enzyme mediating diazepam metabolism.ObjectivesTo investigate the association between CYP2C19*2 (c.681G > A), CYP2C19*3 (c.636G > A), and CYP2C19*17 (-806 C > T) polymorphisms and clinical outcomes—specifically treatment efficacy and respiratory adverse effects—following intravenous diazepam administration in children with seizures.MethodsThis prospective, single-center cohort study enrolled 100 pediatric patients (0–18 years) treated with IV diazepam for febrile/afebrile seizures. Genetic analysis was performed using next-generation sequencing. Clinical endpoints included seizure control following one or two diazepam doses and the incidence of respiratory complications. Statistical analyses assessed associations between CYP2C19 genotypes and seizure control outcomes.ResultsThe median age was 4.5 years (IQR: 2.4–8.5); 61% were male. Overall, seizure cessation was achieved in 76% with the first dose of IV diazepam and in 79% cumulatively. Respiratory side effects were observed in 15% of patients, with 9% requiring positive pressure ventilation. The CYP2C19*2 and CYP2C19*17 alleles were identified in 19% and 49% of participants, respectively. However, the CYP2C19*3 variant was absent. Notably, the presence of the CYP2C19*17 CT/TT genotype—particularly in combination with the CYP2C19*2 GG genotype—was significantly associated with both diazepam treatment failure (p = 0.038) and increased risk of respiratory adverse effects (p = 0.005).ConclusionThis study is the first to delineate the clinical relevance of CYP2C19 polymorphisms in a Turkish pediatric population treated with diazepam. The findings underscore the potential utility of pharmacogenetic profiling to predict therapeutic response and enhance the safety of benzodiazepine use in pediatric seizure management.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40360-026-01159-3.Keywords: Seizures, Antiseizure drugs, CYP2C19, Genetic polymorphism, Pharmacogenetics Introduction Seizures are among the most common neurological disorders in childhood and can lead to significant morbidity and mortality if not treated promptly and effectively [1]. Various antiseizure medications are employed in the acute management of seizures. Diazepam, a benzodiazepine derivative, is one of the most commonly used drugs in this context [2]. Variability in the effectiveness and adverse effects of diazepam has been reported and may be related to the pharmacogenomic characteristics of the patients [3]. While some individuals achieve effective seizure control with a single dose of diazepam, others may require higher doses to attain similar results [4]. Additionally, the same dosage can lead to severe respiratory depression in certain patients, while others tolerate even higher doses without experiencing adverse effects [5]. This inconsistency in response underscores the fact that diazepam does not exert uniform effects across all patients at equivalent doses. This variability highlights the influence of pharmacogenomic factors as well as seizure semiology and the timing of the drug administration. Evidence from adult populations further supports the clinical relevance of CYP2C19 variation for diazepam outcomes. In alcohol withdrawal syndrome, CYP2C19 polymorphisms—particularly the increased-function *17 allele—have been associated with differences in diazepam exposure and variable treatment response and tolerability, highlighting clinically meaningful inter-individual variability in real-world use; although the clinical context differs from pediatric convulsive status epilepticus, these findings provide a rationale for investigating CYP2C19-driven variability in acute benzodiazepine treatment [6, 7]. Pharmacokinetic/pharmacogenetic studies further support biological plausibility. Zubiaur et al. demonstrated an association between CYP2C19 phenotype and diazepam exposure and also underscored that additional metabolic pathways (e.g., CYP2B6) may contribute to diazepam pharmacokinetic variability [8]. Diazepam pharmacogenetics is largely influenced by functional variation in CYP2C19, a key enzyme involved in its biotransformation [6, 7]. Reduced-function alleles such as CYP2C19 *2/*3 may decrease clearance and prolong drug effects, whereas the increased-function allele CYP2C19*17 is associated with faster clearance and variable clinical response [7]. Accordingly, CYP2C19 genotype can contribute to inter-individual differences in diazepam efficacy and the risk of adverse effects, including respiratory depression [6, 7]. Diazepam is primarily metabolized by the cytochrome P450 enzyme CYP2C19 [6]. This metabolic pathway is crucial for the drug’s pharmacokinetics and therapeutic efficacy. Variability in CYP2C19 activity due to genetic polymorphisms can significantly influence individual responses to diazepam, leading to differences in drug metabolism and potential adverse effects [7]. Studies have shown that patients with different CYP2C19 genotypes exhibit varying levels of drug clearance, which can affect the efficacy and safety of diazepam treatment [6–10]. Specifically, individuals classified as poor metabolizers may experience prolonged drug effects, potentially increasing the risk of adverse reactions due to slower clearance. In contrast, those with rapid metabolizer phenotypes may face reduced therapeutic efficacy and, unexpectedly, a higher risk of adverse reactions, possibly due to pharmacodynamic factors. Understanding the role of CYP2C19 in diazepam metabolism is essential for optimizing future treatment regimens and minimizing the risk of complications, particularly in populations with known genetic variations. This highlights the importance of pharmacogenetic testing in personalizing diazepam therapy to enhance patient outcomes. Specifically, three polymorphisms in CYP2C19 significantly influence the efficacy of medications by altering the enzyme’s activity [10, 11]. The CYP2C19*2 allele has the dbSNP reference identifier rs4244285. This polymorphism results from a G→A substitution at the 681st nucleotide position of the cDNA sequence in exon 5, causing a splicing defect. In individuals with the CYP2C19*2 polymorphism, the enzyme activity is reduced, leading to slower drug metabolism and prolonged drug activity. The CYP2C19*3 allele is associated with the dbSNP reference identifier rs4986893. It involves a G→A substitution at the 636th nucleotide position of the cDNA sequence in exon 4, introducing a premature stop codon. This polymorphism reduces CYP2C19 enzyme activity, also prolonging the duration of drug effects. The CYP2C19*17 allele corresponds to the dbSNP reference identifier rs12248560. This polymorphism involves a C→T substitution at position − 806 in the coding region, enhancing gene transcription. In individuals with the CYP2C19*17 polymorphism, the enzyme metabolizes drugs more rapidly, resulting in shorter drug activity and quicker drug clearance. This study aims to evaluate the influence of three polymorphisms in the CYP2C19 gene [CYP2C19*2 (c.681G > A), CYP2C19*3 (c.636G > A), and CYP2C19*17 (-806 C > T)] on the seizure cessation rate and the potential adverse effects of diazepam in a single-center pediatric population. Materials and methods Study design and population This prospective observational follow-up study was conducted at the Pediatric Emergency Department (ED) of a tertiary care hospital in Turkey between January 2021 and May 2023. The cohort consisted of 100 patients aged 0–18 years who presented with seizures and were treated with intravenous (IV) diazepam. Patients with liver failure or those using medications affecting CYP2C19 enzyme activity (e.g. clopidogrel, voriconazole, omeprazole) and/or patients with epilepsy who were given diazepam before admission to the ED (at home or during transport) were excluded from the study. Patients with developmental and epileptic encephalopathies including Lennox–Gastaut syndrome and other established epileptic encephalopathy syndromes were excluded. Ethical approval was granted by the Ege University institutional review board in accordance with the Declaration of Helsinki (Approval date: 2020, number: 20-7.1T/15). Written informed consent was obtained from the parents or legal guardians of all participants before enrollment. The study was supported by the Scientific Research Projects of Ege University (No: 22277). Demographic information, clinical characteristics during the 24-hour follow-up period, presence of chronic diseases, use of antiseizure or other medications, history of head trauma, and clinical outcomes were documented in the case report forms. To maintain patient confidentiality, the forms did not include any data that would have enabled identification of any patients. Study protocol Patients were managed in the Ege Emergency Department following the departmental convulsive status epilepticus (CSE) protocol (Revised- Ege Pediatric Status Epilepticus Protocol called r-EPSEP) and the American Epilepsy Society status epilepticus treatment guideline [2, 12]. According to the guideline, each patient included in the study received 0.2 mg/kg of IV diazepam over an infusion period of more than 1 min. If the seizure did not stop within 5 min, a second dose of diazepam was administered at the same dose. Seizure cessation was accepted as the termination of observable motor seizure activity. Treatment failure was defined as the inability to control seizures or the recurrence of a previously controlled seizure lasting longer than 5 min. Side effects developing after anticonvulsant therapy, including respiratory depression, transient desaturation, hypotension, allergic reactions, and other common side effects of each drug, were noted. Respiratory depression was defined as requiring positive pressure ventilation or endotracheal intubation, or situations where breathing became shallow, and accessory respiratory muscles were used. Transient desaturation was defined as oxygen saturation (SpO2) dropping below 90% for more than 2.5 min [13]. A case report form was completed for each patient who agreed to participate in the study, and 2 mL of blood was drawn into an EDTA tube. The blood samples were stored at -80 °C until genetic analysis. After the collection of all samples, genetic analyses were performed. Genetic analysis DNA was extracted from whole blood samples using the QIAamp DNA Mini Kit (Qiagen), following the manufacturer’s instructions. The purity and concentration of the DNA were measured using a NanoDrop ND-1000 Spectrophotometer. Only DNA samples meeting the required quality and concentration criteria were used for sequencing. The sequence analysis focused on specific regions related to the polymorphisms outlined in the study’s objectives. The analysis specifically targeted the CYP2C19*2 (c.681G > A), CYP2C19*3 (c.636G > A), and CYP2C19*17 (-806 C > T) polymorphisms, as these are well-known to have significant effects on diazepam metabolism. These polymorphisms were selected due to their recognized impact on the enzymatic activity of CYP2C19, which plays a key role in the metabolism of diazepam [14]. Web-based free “Primer3” software was used to select primers suitable for amplifying a region of approximately 300–500 bp containing the polymorphisms (rs4244285, rs4986893, rs12248560) in the CYP2C19 gene. The primers were designed to be 18–24 bp in length, with a GC content of 30–50%, binding to a single region of the DNA, and a melting temperature (Tm) of 58–62 °C. Polymerase Chain Reaction (PCR) was used to amplify the target regions. Each reaction mixture, prepared in a 25 µL volume, contained 0.4 µM of each primer, 2 ng of genomic DNA, 4 mM MgCl2, 0.05 µl Taq DNA polymerase, and 0.4 mM of each dNTP. Twelve such mixtures were prepared in PCR tubes. Amplification was carried out under optimized conditions in a thermal cycler. After amplification, the PCR products were verified by agarose gel electrophoresis. A 2% agarose gel was prepared by dissolving agarose in TBE buffer, with ethidium bromide added after the solution cooled. The PCR products were mixed with loading dye and loaded into the gel along with a DNA ladder. Electrophoresis was conducted at 120 volts, and the gel was visualized under UV light using a gel documentation system. After verification of the target amplicons by agarose gel electrophoresis, the PCR products were prepared for sequencing. Sequencing was performed using the Illumina MiSeq platform, which generated FastQ files. These files were subsequently assembled into BAM files for detailed analysis. Sequence alignment and variant identification were conducted using the Integrative Genomics Viewer (IGV). Allelic variants in the CYP2C19*2 (c.681G > A), CYP2C19*3 (c.636G > A), and CYP2C19*17 (-806 C > T) genes were meticulously identified and annotated for each subject in the study cohort. To facilitate clinical interpretation and to reduce sparse strata in genotype-level analyses, CYP2C19 diplotypes were additionally collapsed into predefined functional metabolizer categories using established Clinical Pharmacogenetics Implementation Consortium allele-function and genotype-to-phenotype translation frameworks. In this approach, *2 and *3 are treated as no-function alleles and *17 as an increased-function allele; importantly, diplotypes carrying one no-function and one increased-function allele (e.g., *2/*17) are classified as intermediate metabolizers, as the increased-function allele does not fully compensate for a no-function allele. Analyses are presented using both genotype-level results and these guideline-based functional groupings [14]. Statistical analysis Allelic and genotypic frequencies of the CYP2C19*2 (c.681G > A), CYP2C19*3 (c.636G > A), and CYP2C19*17 (-806 C > T) polymorphisms were assessed in the study cohort. While the initial calculation estimated that approximately 115 patients might be needed to achieve the desired power, adjustments for study design, anticipated dropout rates, and other factors resulted in a final requirement of 96 patients to ensure a statistical power of 80% with a significance level of p < 0.05 [15–16]. The results were analyzed using the CLC Bio program. For each patient, the bases at the targeted alleles were recorded. Descriptive statistics for categorical variables are presented as frequencies and percentages, and for continuous variables as mean ± standard deviation or median (range). The presence of normal distribution was assessed using histograms, Q-Q plots, and normality tests. Categorical variables were compared using the Pearson chi-square test or, in cases where assumptions were not met, Fisher’s exact test. For comparing continuous variables between two groups, the t-test for independent groups was used if normal distribution was present, or the Mann-Whitney U test was used if normal distribution was absent. A two-tailed p-value of < 0.05 was considered statistically significant. Data analysis was performed using SPSS (Statistical Package for the Social Sciences) version 20. Results Demographics Overall, 100 patients who presented with prolonged seizure and were treated with IV diazepam in the departmental CSE protocol called (r-EPSEP) were included. The median age was 4.5 years (min 2 months – max 17.0 years, IQR 2.4–8.5 years), and the female/male ratio was 1.5/1 (61/39) in patients (Table 1). While 61.0% of the patients were transported to the ED by ambulance, 39.0% were brought in by parents. The frequency of chronic diseases and epilepsy and the rate of antiseizure medication use are shown in Table 1. Febrile seizures were observed in 16.0% of the patients, while trauma was identified in one case and seizure-triggering drug use was detected in three cases. Table 1Demographic characteristics of patients in the studyAge (year) [median (IQR)]4.5 (2.4 – 8.5)Gender (n) (M/F)39 / 61Transport type (n, %) by parents39 (39.0) by ambulance61 (61.0)Underlying chronic diseases (n, %) Epilepsy33 (33.0) Other7 (7.0) None60 (60.0)ASM usage (n, %) +42 (42.0) -58 (58.0)Febrile seizure (n, %) +16 (16.0) -84 (84.0)Trauma history (n, %) +1 (1.0) -99 (99.0)Seizure-triggering drug use (n, %) +3 (3.0) -97 (97.0)Diagnosis (n, %) Epilepsy52 (52.0) Febrile convulsion34 (34.0) NMD5 (5.0) Trauma1 (1.0) Other8 (8.0) Epilepsy types Clinical Focal11 (21.1) Generalized41 (78.9) Etiological Structural12 (23.1) Genetic19 (36.5) Developmental14 (26.9) Epileptic encephalopathy7 (13.5)ASM: antiseizure medications, F: female, IQR: interquantile range, M: male, NMD: neurometabolic disease Demographic characteristics of patients in the study ASM: antiseizure medications, F: female, IQR: interquantile range, M: male, NMD: neurometabolic disease Seizure cessation rates and respiratory side effects Seizures were controlled in 76% of the patients following the initial dose of IV diazepam. These patients were referred to as diazepam first-dose responsive group (n = 76). However, the remaining 24 patients received a second dose of IV diazepam and were referred to as the diazepam first-dose refractory group. In the diazepam first-dose responsive group, 7 of 76 (9.2%) patients experienced recurrent seizures requiring a second dose of IV diazepam. Consequently, 31 patients (31%) received a second dose of IV diazepam. The success rate of second-dose IV diazepam was defined as 32.2% (n = 10/31). The cumulative success rate of two consecutive IV diazepam doses was 79% (N = 79/100) in the study cohort (Fig. 1). Flowchart of received IV diazepam administration and treatment success Respiratory side effects were observed in 15% of the patients (n = 15). Among these patients, 40% (n = 6) experienced transient desaturation, while 60% (n = 9) developed respiratory depression, requiring positive pressure ventilation. More than half (52.0%) of the patients included in the study were diagnosed with epilepsy, while 34.0% had febrile convulsions (28.0% complicated, 6.0% simple). Age, gender, and the presence of epilepsy were found to have no effect on treatment failure and respiratory side effects following diazepam treatment (Tables 2 and 3). Table 2Clinical and genotype characteristics for IV diazepam efficacy for seizure controlDiazepam response -/+ [n (%)]UnivariateMultivariateOR95% CI p OR95% CI p Gender Male (R)Dec-27 FemaleSep-520.40.1–1.0 0.053 0.50.2–1.1 0.089 Age (year) >5 (R)Aug-38 ≤513/410.50.2–1.6 0.261 1.10.5–2.7 0.812 Underlying epilepsy disease No (R)Nov-46 YesOct-330.60.2–1.8 0.415 0.30.1–0.7 0.415 Genotype CYP2C19*2 GG16/65 GA or AAMay-140.60.2–1.9 0.397 0.70.2–2.4 0.581 CYP2C19*17 CC15/36 CT or TTJun-430.50.1–7.9 0.078 0.30.1–9.2 0.147 Genotype § CYP2C19*2 - CYP2C19*17 GG – CC (Normal)7 (16.3) / 36 (83.7)0.50.2–1.3 0.145 2.10.8–5.7 0.154 GG – CT/TT (Fast)11 (28.9) / 27 (71.1)1.30.9–4.9 0.265 0.40.2–6.1 0.367 GA/AA – CC (Slow)2 (25.0) / 6 (75.0)0.50.1-3.0 0.559 0.30.3-9.0 0.522 GA/AA – CT/TT (IM)1 (9.1) / 10 (90.9)0.60.1–3.6 0.637 0.10.1–3.6 0.586 OR: Odds-ratio, CI: confidence interval ß Univariate and multivariate logistic regression analysis § Enzyme activity based on previously published report Clinical and genotype characteristics for IV diazepam efficacy for seizure control OR: Odds-ratio, CI: confidence interval ß Univariate and multivariate logistic regression analysis § Enzyme activity based on previously published report Table 3Predictors for respiratory side effects following diazepam treatmentsRespiratory side effect +/- [n (%)]UnivariateMultivariateOR95% CI p OR95% CI p Gender Male (R)Aug-53 FemaleJul-320.80.2–2.8 0.73 1.40.4–4.6 0.591 Age (year) >5 (R)Jul-39 ≤5Aug-461.10.3–4.3 0.928 1.30.3–6.5 0.712 Underlying epilepsy disease No (R)Sep-48 YesJun-370.90.2–3.6 0.922 10.2–3.5 0.981 Genotype CYP2C19*2 GGNov-70 GA or AAApr-151.50.4–5.6 0.58 1.70.5–6.6 0.387 CYP2C19*17 CCFeb-49 CT or TT13/368.81.9–41.7 0.02 8.91.8–42.6 0.006 Genotype § CYP2C19*2 - CYP2C19*17 GG – CC (Normal)1 (2.3) / 42 (97.7)0.10.1–1.2 0.075 0.10.1–1.2 0.068 GG – CT/TT (Fast)11 (28.2) / 28 (71.8)10.31.2–86.7 0.031 9.71.1–82.9 0.038 GA/AA – CC (Slow)1 (12.5) / 7 (87.5)0.40.1–3.5 0.415 0.80.2–5.1 0.637 GA/AA – CT/TT (IM)2 (18.2) / 9 (81.8)0.90.1–7.8 0.907 4.70.3–83.7 0.284 OR: Odds-ratio, CI: confidence interval ß Univariate and multivariate logistic regression analysis § Enzyme activity based on previously published reports Predictors for respiratory side effects following diazepam treatments OR: Odds-ratio, CI: confidence interval ß Univariate and multivariate logistic regression analysis § Enzyme activity based on previously published reports The relationship with CYP2C19 polymorphisms and seizure cessation rates and respiratory side effects The allelic and genotypic frequencies of CYP2C192 (c.681G > A) and CYP2C1917 (-806 C > T) were 19% (n = 19) and 49% (n = 49), respectively. However, none of the patients had CYP2C19*3 (c.636G > A) polymorphisms. Of the CYP2C19*2 (c.681G > A) polymorphisms, 18 were heterozygous (GA), while 1 was homozygous (AA). In CYP2C19*2 (c.681G > A), the frequencies of the G and A alleles were observed as 90% and 10%, respectively. Among the CYP2C19*17 (-806 C > T) polymorphisms, 44 were identified as heterozygous (CT), and 5 as homozygous (TT). For CYP2C19*17 (-806 C > T), the C allele frequency was 73%, while the T allele frequency was 27%. Also, CYP2C19*2 and CYP2C19*17 genotypes, polymorphisms, and functions were shown in Table 4. Table 4CYP2C19*2 and CYP2C19*17 genotypes, polymorphisms, and functionsPolymorphismGenotypeEnzyme activity%CYP2C19*2CYP2C19*17CYP2C19*2CYP2C19*17--GGCCNormal43-+GGCT / TTFast38+-GACCSlow8++GACTIntermediate11CYP2C19*2 (c.681G > A), CYP2C19*17 (-806 C > T) CYP2C19*2 and CYP2C19*17 genotypes, polymorphisms, and functions CYP2C19*2 (c.681G > A), CYP2C19*17 (-806 C > T) The association of CYP2C19*2 and CYP2C19*17 polymorphisms with diazepam treatment failure and respiratory side effects was analyzed both individually and through cosegregation, as demonstrated in Tables 3 and 4. The frequency of respiratory side effects and treatment failure was statistically significantly higher in patients with the CT or TT genotype in the CYP2C19*17 gene and the GG genotype in the CYP2C19*2 gene (OR: 8.8, 95% CI: 1.9–41.7) (p = 0.020). Discussion In this cohort study we investigated the relationship between three polymorphisms in the CYP2C19 gene [CYP2C19*2 (c.681G > A), CYP2C19*3 (c.636G > A), and CYP2C19*17 (-806 C > T)] and IV diazepam application in a pediatric cohort with CSE treated with r-EPSEP. The allelic and genotypic frequencies of the CYP2C19*2 (c.681G > A), and CYP2C19*17 (-806 C > T) were 19% and 49% respectively. However, none of the patients had CYP2C19*3 (c.636G > A) polymorphisms. We also identified that the CYP2C19*17 CT/TT genotype—particularly in combination with the CYP2C19*2 GG genotype was significantly associated with both diazepam treatment failure (p = 0.038) and increased risk of respiratory adverse effects [2–4]. The effectiveness of IV diazepam in managing convulsions has been evaluated in various studies across different populations and it generally has a seizure-terminating efficacy of 70% to 90% after two doses [17–19]. Similar to previous studies, seizure control with IV diazepam was successfully achieved in 79% of patients in our study. Our findings indicate a significant relationship between the CYP2C19*17 polymorphism and the occurrence of respiratory side effects, particularly when co-occurring with the wild-type GG genotype of CYP2C19*2, suggesting that the combined presence of both genetic polymorphisms might have a critical role in the pharmacokinetics and pharmacodynamics of diazepam in children [2–4]. The metabolism of diazepam is primarily mediated by the CYP2C19 enzyme, and genetic variations in this enzyme can lead to significant differences in drug clearance and efficacy [14, 15]. The CYP2C19*2 (rs4244285), CYP2C19*3 (rs4986893), and CYP2C19*17 (rs12248560) SNPs (Single Nucleotide Polymorphism) in the CYP2C19 gene are known to significantly impact on medication efficacy through modifications in the enzyme’s activity [20, 21]. These SNPs may exhibit regional and ethnic differences. A study conducted by Ahmet et al. reported the prevalence of CYP2C19*2 and CYP2C19*3 gene variants across six distinct ethnic groups in Pakistan. They found that the prevalence of the CYP2C19*2 gene variant ranged from 4.5% to 27.66%, while the prevalence of the CYP2C19*3 gene variant varied between 2.88% and 15% [19, 22]. The CYP2C19*17 gene variant showed a prevalence between 11% and 34% in various regions of China, while it was detected at a higher rate of 43% among Russian patients [23, 24]. In our study conducted in Turkish population, 19% were found to carry the CYP2C19*2 polymorphism, 49% had the CYP2C19*17 polymorphism, and none exhibited the CYP2C19*3 polymorphism. Previous research has highlighted the significant impact of pharmacogenetic factors on individual variability in response to diazepam [2–4]. Diazepam is primarily metabolized by the CYP2C19 enzyme, and polymorphisms in this gene can lead to significant differences in drug metabolism [25]. Specifically, individuals with the CYP2C19*2 allele are known to be poor metabolizers, while those with the CYP2C19*17 allele exhibit increased enzyme activity, resulting in faster drug clearance [9–11]. The findings of our study showed that patients carrying the CYP2C19*17 SNP, when co-occurring with the GG genotype of CYP2C19*2, experienced higher rates of respiratory side effects. We found that, interestingly this gene variant was associated with a high rate of respiratory side effects, despite its expected rapid metabolism. This suggests that in addition to pharmacokinetic factors related to metabolism, the pharmacodynamic effects of a drug can also play a significant role in the development of side effects, and these effects may vary between individuals. This may reflect exposure–response variability and mechanisms beyond metabolism alone. Indeed, diazepam is also metabolized via CYP3A4, and both CYP2C19 and CYP3A4 metabolise diazepam to pharmacologically active metabolites, initially to nordiazepam and temazepam and further to oxazepam. These active metabolites may add to overall benzodiazepine exposure and could contribute to respiratory adverse effects in susceptible patients. However, we did not measure diazepam or nordiazepam concentrations in this cohort; therefore, we cannot directly evaluate whether the observed respiratory adverse effects were mediated by increased metabolite exposure. Future studies incorporating parent drug and metabolite concentrations (ideally together with pharmacogenetic data) would help clarify the relative contribution of active metabolites to respiratory safety outcomes. Individual differences, such as genetic factors, age, gender, and overall health, can influence how the drug is metabolized and how it exerts its effects in the body. As a result, the same drug may cause different side effects in different people. Concomitant antiseizure medications may also influence diazepam exposure through CYP modulation; potential interactions with commonly used ASMs (e.g., carbamazepine, phenobarbital, and phenytoin) are summarized in Supplementary Table S1. Despite the strengths of our study, including its prospective design and the use of next-generation sequencing for genetic analysis, several limitations should be acknowledged. These findings should be considered hypothesis-generating rather than causal and warrant replication in adequately powered studies. The sample size, while adequate for preliminary findings, may limit the generalizability of the results. Additionally, the study was conducted at a single center, which may introduce selection bias and limit the applicability of the findings to broader populations. Therefore, the clinical implications should be interpreted cautiously, as the findings may not extrapolate to other centers, different CSE management pathways, or pediatric populations with different demographic/ethnic backgrounds. Confirmation in larger, multicenter cohorts is warranted to support external validity. Furthermore, the follow-up period of 24 h may not capture all potential side effects or long-term treatment responses, as some adverse effects may manifest later. Because EEG confirmation was unavailable, our efficacy endpoint may misclassify a subset of patients with persistent electrographic seizures/non-convulsive status epilepticus as clinical responders, potentially inflating the apparent treatment success rate. Continuous EEG studies in pediatric CSE have shown that electrographic-only seizures can occur after convulsive seizure control, underscoring this limitation. Chronic exposure to these medications may induce pharmacodynamic tolerance and influence both the clinical efficacy of diazepam and the risk of respiratory adverse events, and therefore represents a potential confounder that could not be fully accounted for in our analyses. Finally, residual confounding due to concomitant ASM use and potential drug–drug interactions cannot be fully excluded (Supplementary Table S1). Conclusion In conclusion, the presented cohort study describes the genetic landscape of the CYP2C19 polymorphisms in a pediatric cohort treated with IV diazepam and highlights its differences in prevalence between treatment-responsive and refractory groups. The combined presence of two polymorphisms (CYP2C19*17 CT/TT genotype and CYP2C19*2 GG genotype) is associated with an increased risk of respiratory adverse effects of IV diazepam within a departmental protocol. Additional prospective long-term follow-up studies involving a larger number of patients in more diverse cohorts may provide deeper insights into the relationship between genetic variation and clinical outcomes, ultimately advancing personalized approaches in the CSE protocols. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements We would like to thank Prof. Dr. Sibel Goksel from Ege University Faculty of Medicine, Department of Pharmacology, for her expert pharmacological consultation and critical input regarding diazepam metabolism, active metabolites, and potential drug–drug interactions, which helped improve the scientific interpretation of the manuscript. Author contributions Conceptualization, analysis, and manuscript drafting: MSG, CT, DAY, TA and EUS; Clinical management and follow-up: MSG, CT, AY, SK, SKY; Laboratory data interpretation: MSG, DAY, EI, SK and TA; Literature Review: MSG, CT, TA, HT and EUS; Critical revision of the manuscript: CT, TA, HT and EUS; All authors contributed to all stages of the work, reviewed the final version of the manuscript, and approved it for submission. Funding The study was supported by the Scientific Research Projects of Ege University (No: 22277). Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of Ege University Faculty of Medicine with decision number 20-7.1T/15 and was conducted in accordance with the Declaration of Helsinki and subsequent ethical standards. Written informed consent was obtained from the parents or legal guardians of all pediatric patients included in this study. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.